Gastrodia elata prevents huntingtin aggregations through activation of the adenosine A2A receptor and ubiquitin proteasome system

Abstract

Ethnopharmacological relevanceGastrodia elata Blume (Fam. Orchidaceae) is a traditional Chinese herbal medicine for treating headaches, dizziness, tetanus, epilepsy, and numbness of the limbs, which suggests that it has neuroprotective effect. Aim of the studyTo validate the neuroprotection of Gastrodia elata in preventing neurodegenerations, such as Huntington's disease (HD). Materials and methodsMTT assay was used to validate the protection of Gastrodia elata. In pheochromocytoma (PC12) cell. Transient transfection of mutant huntingtin (Htt) in PC12 cell was used as an in vitro model of HD. Filter retardation assay was used to measure Htt-induced protein aggregations. Proteasome activity was monitored by transfection of pZsProSensor-1 and imaged by a confocal laser scanning microscope. ResultsThis protection of Gastrodia elata could be blocked by an A2A-R antagonist and a protein kinase A (PKA) inhibitor, indicating an A2A-R signaling event. Gastrodia elata could reverse mutant Htt-induced protein aggregations and proteasome de-activation through A2A-R signaling. In addition, activation of PKA tended to activate proteasome activity and reduce mutant Htt protein aggregations. The proteasome inhibitor, MG 132, blocked Gastrodia elata-mediated suppression of mutant Htt aggregations. ConclusionGastrodia elata prevented mutant Htt aggregations and increased proteasomal activity by targeting the A2A-R through PKA-dependent pathway.